Creative Biolabs provides an integrated platform for assessing the biological effects of substances on reproductive and developmental processes. Our service provides a combination of traditional laboratory testing and next-generation predictive modeling. By partnering with us, clients can expect to gain a deep mechanistic understanding of their compounds, clear data on dose-response relationships, and robust evidence to support internal decision-making or technical submissions. We bridge the gap between initial compound synthesis and comprehensive biological profiling, ensuring that research risks are identified and mitigated early in the development cycle.
Creative Biolabs offers one-stop DART services, ranging from program planning and individual study design to study implementation, in full compliance with international regulatory standards, including ICH and OECD. The scope of our services includes pharmaceuticals (small and large molecules) and biopharmaceuticals (cellular and gene therapy, vaccines).
Discover how we can help - Request a consultation.
Fig.1 Flowchart of experimental design for reproductive and developmental toxicity testing. 1
At Creative Biolabs, we are dedicated to providing studies about male/female fertility and developmental toxicity, including embryo-fetal development, pre-/postnatal development, and multigenerational development, to evaluate the potential safety risks associated with novel therapies on the entire development and reproductive spectrum.
| Our Capabilities | Functional Assays of Evaluation |
|---|---|
|
|
We also offer a full range of rodent and non-rodent species animal models, dose routes ranging from dermal infusion to intravenous infusion to fit your program.
Creative Biolabs maintains a sophisticated laboratory ecosystem coupled with profound scientific proficiency. This infrastructure ensures all segmented investigations, including intricate multi-generational reproductive analyses, are executed within a unified and highly coherent framework.
Our optimized project administration and validated experimental protocols facilitate rapid operational transitions. Consequently, latency between initial candidate selection and empirical data acquisition is minimized, providing a significant competitive advantage in research timelines.
We converge contemporary laboratory apparatus with advanced computational methodologies. By synthesizing automated analytical pipelines with predictive modeling, Creative Biolabs establishes a robust empirical foundation that potentially transcends the limitations of traditional paradigms.
Our investigators employ nuanced dose-selection algorithms to pinpoint discrete biological hazards while preempting confounding toxicity. This "Fail Fast" methodology serves to optimize the allocation of research capital and budgets.
Discover how a partnership with us can streamline your research - Get a quote today.
We speculate that initiating screening during the lead-optimization phase is optimal. This allows for the early identification of biological hazards before significant capital is committed to a specific molecular series.
We adopt a hypothesis-driven framework that harmonizes the necessity for hazard identification with established laboratory welfare standards. This approach avoids non-specific effects that might otherwise obfuscate the data.
High-throughput screening is designed to assess the absorption, distribution, metabolism, and excretion of candidates, providing critical pharmacokinetic insights.
Learn More →Advanced LC-MS-based bioanalysis for the high-sensitivity quantification of drugs and metabolites within complex biological matrices, facilitating precise research-driven safety assessments.
Learn More →Creative Biolabs offers comprehensive, state-of-the-art DART services to help our clients make smarter decisions faster. We are dedicated to pioneering advances in DART studies to move your program into IND approval. Please contact us for more detailed information.
Reference